ReviewImmunologic research2007
IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity.
Review in Immunologic research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 176 citations in OpenAlex.
- The Cross-Knit Between Immune Cells and Thyroid Function in Autoimmune Thyroid Disorders: What We Can Learn from Inborn Errors of Immunity.Children (Basel, Switzerland) · 2026Review
- Adult-onset Still's disease masquerading as acute coronary syndrome: a case report and review of the literature.Journal of medical case reports · 2024Review
- Legumain Regulates Regulatory T Cells in Hypertension.Circulation research · 2024Article
- Genetic perspectives on childhood monogenic diabetes: Diagnosis, management, and future directions.World journal of diabetes · 2023Review
- TCF-1 negatively regulates the suppressive ability of canonical and noncanonical Tregs.Journal of leukocyte biology · 2023Article
- Regulatory T cells suppress CD4+ effector T cell activation by controlling protein synthesis.The Journal of experimental medicine · 2023Article
- Immunomodulatory actions of vitamin D in various immune-related disorders: a comprehensive review.Frontiers in immunology · 2023Review
- Treg in inborn errors of immunity: gaps, knowns and future perspectives.Frontiers in immunology · 2023Review
- Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis.Cancer research communications · 2022Article
- Article
- Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases.Nature reviews. Rheumatology · 2022Review
- Druggable monogenic immune defects hidden in diverse medical specialties: Focus on overlap syndromes.World journal of clinical pediatrics · 2022Review
- Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications.Nutrients · 2022Review
- Tissue Resident Foxp3Frontiers in immunology · 2022Review
- Toward a mechanistic understanding of DNA binding by forkhead transcription factors and its perturbation by pathogenic mutations.Nucleic acids research · 2021Review
- The double-edged sword of Tregs in M tuberculosis, M avium, and M absessus infection.Immunological reviews · 2021Review
- Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic?Circulation research · 2021Review
- The thymus medulla and its control of αβT cell development.Seminars in immunopathology · 2021Review
- IL-2 Signaling Axis Defects: How Many Faces?Frontiers in pediatrics · 2021Review
- Atypical Presentations of IPEX: Expect the Unexpected.Frontiers in pediatrics · 2021Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
FOXP3 is the key mediator of regulatory T-cell development in the thymus. Naturally occurring mutations of FOXP3 interfere with this process, resulting in the generation of autoaggressive lymphocyte clones that are directly responsible for the syndrome Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) in humans and scurfy in mice. Stem cell transplantation is the only cure for IPEX patients. The study of this rare disease has provided important insight into the mechanisms of immunosuppression, autoimmunity and tolerance and future studies may lead to novel strategies to treat not only patients with IPEX, but also those suffering from autoimmunity, graft-versus-host disease or cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.